Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 16/20 | 0.72 |
| ▸ | GRPR | P30550 | 15/20 | 0.72 |
| ▸ | FPR1 | P21462 | 5/20 | 0.72 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.58 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.58 |
| ▸ | FPR2 | P25090 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6252249 | 1.00 | NMBR (0.72) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6253303 | 0.93 | NMBR (0.62) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6810086 | 0.93 | NMBR (0.62) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6253532 | 0.90 | NMBR (0.58) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL7654323 | 0.89 | NMBR (0.72) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6250987 | 0.89 | NMBR (0.72) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6251024 | 0.88 | NMBR (0.55) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6254936 | 0.88 | NMBR (0.55) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6251562 | 0.86 | NMBR (0.63) | NMBRGRPRFPR1AGTR1GPR65 | |
| SCHEMBL6254175 | 0.85 | NMBR (0.53) | NMBRGRPRFPR1AGTR1GPR65 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | claimed |
| EP-1333824-A2 | TREATMENT OF SEXUAL DYSFUNCTION | Warner-Lambert Company LLC (US) | 2003-08-13 | — | — | EP | claimed |
| WO-2002040008-A2 | TREATMENT OF SEXUAL DYSFUNCTION WITH NON PEPTIDE BOMBESIN RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-23 | — | — | WO | claimed |
| US-20040087561-A1 | Treatment of sexual dysfunction | WARNER-LAMBERT COMPANY LLC | 2004-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087561-A1 | Treatment of sexual dysfunction | BRS3, MME, ECE1 | NMBR 258/4885GRPR 199/4885FPR1 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.